• Recordati confirmed its 2026 financial targets, with results expected at the upper end of guidance ranges.
• Revenue is forecast at EUR 2.73 billion–EUR 2.8 billion, supported by high-teens organic growth in Rare Diseases at constant exchange rates.
• EBITDA is projected at EUR 995 million–EUR 1.03 billion, with a margin of approximately 36.5%.
• Adjusted net income is targeted at EUR 655 million–EUR 685 million, implying a margin of approximately 24%.
• Nine-month revenue rose 7.5% to EUR 2.1 billion; Rare Diseases sales grew 18.7%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recordati Industria Chimica e Farmaceutica S.p.A. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.